Pharmacological profile and mechanism of action
Etomidate (Etomidatum) is a chemical compound from the carboxylated imidazole group. In clinical practice, it is used primarily for induction or balanced anesthesia.
The key mechanism of action of the drug involves the potentiation of GABA (gamma-aminobutyric acid) effects in the central nervous system. By this mechanism, etomidate is similar to another popular anesthetic, propofol.
Upon intravenous administration, the drug demonstrates high pharmacological activity and is classified as an ultra-short-acting agent. It reliably induces loss of consciousness in the patient for just 3–5 minutes. During anesthesia, two important hemodynamic and neurological aspects should be considered:
- A decrease in blood pressure (BP) is possible.
- Spontaneous muscle movements may be observed in the patient during anesthesia.
Analgesic features
The most important pharmacodynamic feature of etomidate is the complete absence of analgesia.
Despite its high potency in suppressing consciousness, the drug does not block pain impulses at all. This makes its use as a single agent for surgical interventions impossible. To provide adequate surgical analgesia, etomidate must be combined with analgesics, typically opioids.
Side effects and endocrine toxicity
The use of etomidate is associated with a number of side effects. The most frequent clinical manifestation in the postoperative period is frequent vomiting, the risk of which increases particularly when the drug is combined with opioid analgesics.
A key feature of etomidate is its specific endocrine toxicity. The drug selectively inhibits steroidogenesis in the adrenal cortex. Even after a single intravenous injection, the plasma levels of vital hormones significantly decrease:
- Hydrocortisone;
- Aldosterone.
This feature dictates strict limitations on the duration of drug use. The risks of prolonged infusion are associated with the development of acute adrenocortical insufficiency. The clinical picture of such a complication includes:
- Persistent hypotension.
- Pronounced electrolyte imbalance.
- Oliguria (decreased urine output).
To remember the main danger of the drug, use the two "E" rule: Etomidate = Endocrine toxicity (suppresses the adrenals).
Class and exam questions
Can etomidate be used for complete single-agent anesthesia?
No, the drug does not have an analgesic effect (analgesia is absent). It must be combined with opioids.
How does etomidate affect hemodynamics and the muscular system upon administration?
Intravenous administration is marked by a decrease in blood pressure, and spontaneous muscle movements are possible during anesthesia.
What is the danger of prolonged etomidate infusion?
Prolonged infusion leads to adrenocortical insufficiency due to the inhibition of steroidogenesis. This manifests as hypotension, electrolyte disturbances, and oliguria.
What else to study on this topic
- Comparative profile of the mechanisms of action of etomidate and propofol (GABAergic effect).
- Regimens of balanced anesthesia: combination of etomidate with opioids.
- Pathogenesis of electrolyte imbalance and oliguria in decreased aldosterone levels.
- Prevention measures for frequent postoperative vomiting when using a combination of imidazoles and opioids.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Comprehensive study guide on "Etomidate" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the "Special Pharmacology" section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.